Healthcare Compliance

FDA CDER SSRI Listening Session Minutes, March 24, 2026

FDA's Center for Drug Evaluation and Research (CDER) convened an SSRI (Selective Serotonin Reuptake Inhibitor) listening session on March 24, 2026, publishing minutes and three related presentations. Topics addressed included a petition for balanced evidence-based pregnancy warnings on serotonergic drugs and methods for safely deprescribing psychiatric medications. The documents were made available via Regulations.gov docket FDA-2025-P-1305-0288.

Two Measles Cases Confirmed in Maryland Residents with Recent Out-of-State Travel

The Maryland Department of Health announced two confirmed measles cases in Maryland residents of the Baltimore metro area who recently traveled to a U.S. location with active measles transmission. Health officials have identified nine exposure locations including Giant Foods Pasadena, Bean Rush Cafe, Whole Foods Annapolis, and several medical facilities in the Annapolis and Glen Burnie areas, spanning April 12-21, 2026. Exposed individuals should monitor for symptoms for 21 days, verify MMR vaccination status, and contact healthcare providers before visiting medical facilities if symptoms develop.

Company Fined $2,500 for Failing to Comply with Ahpra Investigation

A West Australian court has upheld AHPRA's power to compel evidence production during investigations, marking the first prosecution for this offence under the National Law. Siena Beauty Pty Ltd was fined $2,500 and ordered to pay $5,000 in legal costs after pleading guilty to failing to comply with a Schedule 5 Notice to Produce Information. The company, a practice management company for a registered health practitioner's clinic, failed to provide financial records regarding supplements and alternative treatments despite receiving multiple extensions of time.

Warrant Issued for Banned Occupational Therapist Misheck Mukonoweshuro

NSW man Misheck Mukonoweshuro has been found guilty of four counts related to practising as an occupational therapist while banned, including one count of unlawfully holding himself out as a registered occupational therapist between 12 April 2023 and 6 May 2024. After failing to appear in Liverpool Local Court in March 2026 and again on 10 April 2026, a warrant was issued for his arrest to be brought before the court for sentencing. His registration was previously cancelled by the Civil and Administrative Tribunal NSW in July 2025, prohibiting him from providing health services for five years.

Oregon Volunteers Strengthen Public Health Emergency Response

Oregon Health Authority is recognizing volunteers during National Volunteer Appreciation Week (April 19-25) for their contributions to public health emergency response through the State Emergency Registry of Volunteers in Oregon (SERV-OR) and the AmeriCorps VISTA Partnership Project. The agency spotlights four individual volunteers — Stuart Vaughters, Lucy Rowing, Libet Streiff, Peter Mackwell, and Alex Dolle — representing decades of combined service from disaster medical response to emergency preparedness exercises like Operation Pathfinder. OHA encourages interested Oregonians to learn about volunteer opportunities through SERV-OR and AmeriCorps VISTA.

Eric Robinson OD License Suspended, New Jersey

The New Jersey State Board of Optometrists issued an Order of Summary Suspension against Eric Robinson, OD (License No. 27OA00411100) on April 20, 2026. The suspension stems from Respondent's failure to respond to two Board inquiry letters sent to his address of record, constituting non-cooperation with a Board investigation under N.J.A.C. 13:45C-1.2 and professional misconduct pursuant to N.J.S.A. 45:1-21(e). The license shall remain suspended until further Order of the Board, and Respondent is prohibited from practicing optometry in New Jersey until reinstatement.

DHSC Transparency: Spending Over £25,000, January 2026

The Department of Health and Social Care (DHSC) has published its monthly transparency report detailing all departmental spending exceeding £25,000 for January 2026. The data is available as a downloadable CSV file (260 KB). This disclosure is part of DHSC's routine commitment to government transparency and public accountability.

DHSC Spending Over £25,000, November 2025

The Department of Health and Social Care (DHSC) publishes monthly transparency data on all departmental spending over £25,000. The November 2025 dataset was published on 24 April 2026 as a 224 KB CSV file available for download. This is routine government transparency reporting under the UK's commitment to open public spending data.

DHSC Spending Over £25,000, December 2025

The Department of Health and Social Care (DHSC) published its monthly transparency data on 24 April 2026, disclosing all departmental spending over £25,000 for December 2025. The data is available as a 277 KB CSV file. This is a routine transparency publication; no new compliance obligations, penalties, or regulatory changes are introduced.

IFAD Call for Proposals: 4P4SID Grant for Sustainable Irrigation Development, East and Southern Africa

IFAD has launched a Call for Proposals to select an implementing partner for the 4P4SID grant, which aims to enhance the sustainability of smallholder irrigation schemes in East and Southern Africa through Public-Private Producer Partnership (4P) approaches. The initiative will identify, pilot, and scale innovative partnership models while strengthening stakeholder capacities and producing knowledge products. Proposals must be submitted by 15 May 2026 at 17:00 Rome time (UTC+2).

Acute Hunger Doubles Over Decade as Famine Confirmed in Two Conflict Zones, 266 Million People Face Acute Food Insecurity

The Global Report on Food Crises 2026, released by the Global Network Against Food Crises, reveals that acute hunger has doubled over the past decade, with 266 million people in 47 countries experiencing high levels of acute food insecurity in 2025. For the first time in the report's history, famine was confirmed in two separate contexts in the same year — Gaza Governorate and parts of Sudan — driven primarily by conflict and restricted humanitarian access. Ten countries (Afghanistan, Bangladesh, Democratic Republic of the Congo, Myanmar, Nigeria, Pakistan, South Sudan, Sudan, Syrian Arab Republic, and Yemen) accounted for two-thirds of all people facing high levels of acute hunger. Funding for food crises responses has fallen back to 2016 levels, limiting response capacity.

Method for Producing an Orthopaedic Support Element, Patent EP4188288A1

The European Patent Office has granted patent EP4188288A1 titled 'Method for Producing an Orthopaedic Support Element' to inventor-applicant David Hahlbrock. The patent covers production methods for orthopaedic support elements classified under IPC A61F 5/01 (orthopaedic apparatus) and A61F 5/02 (orthopaedic devices), with additional classification under B29C 33/38 (moulding processes). The granted patent is valid in 32 designated contracting states including Germany, France, the United Kingdom, Italy, and other EPO member states.

Knee Prosthetic Planning System, EP4153044A1, Apr 15

The European Patent Office published patent application EP4153044A1 for a knee prosthetic planning system filed by Little Engine, LLC. The application names five inventors and covers IPC classifications related to prosthetic devices, including A61B 5/103, A61F 2/08, and A61F 2/38. The designated states cover all major European patent validation countries including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Balloon-Expandable Heart Valve System - EP4149394A1, Vitae LLC

The European Patent Office published patent application EP4149394A1 for a balloon-expandable heart valve system and method of implantation filed by Vitae LLC. The application names TIAN, Bin as the sole inventor and falls under IPC classification A61F 2/24 (heart valve prostheses). The publication designates 32 European states where patent protection may eventually be sought. This is an A1 publication — the application has been made publicly available but has not yet been granted.

Medtronic Balloon-Expandable Cardiac Valve Prosthesis Stent Patent EP4114311A1

The European Patent Office published EP4114311A1, a patent application filed by Medtronic, Inc. covering balloon-expandable stents with lengthened commissure posts designed for transcatheter implantation of cardiac valve prostheses. The patent names 17 inventors including Peterson, Kari, Javani, Farrar, Askari, and others, and was published under IPC classification A61F 2/24 on April 15, 2026. The application designates all European member states covered by the EPO.

Edwards Lifesciences EP3860503A1 Stabilizer for Cardiac Valve Delivery Systems

Edwards Lifesciences Corporation filed EP3860503A1 with the European Patent Office for a stabilizer for a delivery system, published on 15 April 2026. The patent application covers IPC classifications A61B 90/57, A61F 2/24, and A61B 90/11, with designated states spanning the EPO member states. Named inventors include JAMAL, Deena; LUONG, Hieu; JOHNSON, Garrett; GUTIERREZ, Tarannum; BECERRA, Matthew; and NESBITT, Karen.

Shape Memory Element for Straightening Malleable Device

The European Patent Office published international patent application EP3975819A1, filed by Biosense Webster (Israel) Ltd., covering a shape memory element designed to straighten malleable medical devices. The application was published on April 15, 2026 and entered the European phase with designations covering all major EU contracting states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands. Medical device manufacturers developing catheter-based or other malleable instruments with shape-memory components should review the published claims to assess potential freedom-to-operate implications.

Canon Image Processing Device, Published 15th Apr

Canon Kabushiki Kaisha obtained a European patent publication (EP3903681A1) for an image processing device and method covering medical imaging applications. The patent, published April 15, 2026, includes IPC classifications A61B 6/03 (CT scanners) and multiple G06T classifications for image segmentation and analysis. Designated states cover 31 European countries including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Nova Biomedical Liver Enzyme Blood Measurement Device EP3823530A1

Nova Biomedical Corporation filed EPO patent application EP3823530A1 for systems and methods measuring liver enzyme levels in blood, covering ALT, AST, ALP, and GGT biomarkers. The application was published on 15 April 2026 with designations extending across 32 EU/EEA states including Germany, France, Italy, Spain, Netherlands, and the United Kingdom. The patent protects point-of-care diagnostic methods and devices for liver enzyme quantification from blood samples.

Biopsy System with Tissue Impedance Measurement, EP4031014A1

European Patent Office published EP4031014A1 on April 15, 2026, disclosing a biopsy system with tissue sample impedance measurement capability. The patent application was filed by Bard Peripheral Vascular, Inc., with inventors Brian Boyle, Ranjani Sampath Kumaran, and Bryon Pelzek. The invention falls under IPC classifications A61B 10/02, A61B 10/00, A61B 5/0538, and A61B 5/00. The designated states cover the full European patent territory including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Economical, Environmentally Friendly, Disposable Blood Pressure Cuff Patent EP3818928A1

The European Patent Office published patent application EP3818928A1 for Welch Allyn, Inc. covering economical, environmentally friendly, disposable blood pressure cuffs and methods of manufacturing. Inventors Raymond A. Lia and Robert L. Vivenzio are listed. The patent was published April 15, 2026 and designates multiple European states including Germany, France, the United Kingdom, Italy, Spain, and others.

Masimo Patient Monitoring Systems, EP3955809A1, A61B

The European Patent Office published European patent application EP3955809A1 for Masimo Corporation's patient monitoring systems and devices on April 15, 2026. The patent application covers multiple IPC classifications including A61B 5/01, A61B 5/1455, A61B 5/021, and A61B 5/024, among others, with inventors including AL-ALI, DEJONG, TELFORT, FULLERTON, and PEREA. The designated states include all major European Patent Convention member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Intuitive Surgical EP3813720A1 Stereoscopic Endoscope Distance Measurement

EPO published European patent application EP3813720A1 for Intuitive Surgical Operations, Inc. on April 15, 2026. The application titled 'SYSTEMS AND METHODS FOR MEASURING A DISTANCE USING A STEREOSCOPIC ENDOSCOPE' covers image-guided surgical systems incorporating stereoscopic endoscopy and computer vision for intraoperative distance measurement. Designated states include all EU member states plus associated European Patent Convention countries, covering a major global market for the disclosed medical device technology.

Roche Diabetes Care Patent for Analyte Sensor Electrode Manufacturing

The European Patent Office published patent application EP4000517A1, filed by Roche Diabetes Care GmbH and F. Hoffmann-La Roche AG, covering a method for manufacturing a working electrode of an analyte sensor. The inventors are listed as Branislav Babic and Alexander Steck. The patent application was published on April 15, 2026 and designates multiple European states. This is a routine patent publication event and does not create compliance obligations for third parties.

Oblong Endoscope Sheath, A61B, 15th Apr

European patent application EP3821786A1 titled "Oblong Endoscope Sheath" was published by the EPO on April 15, 2026, with applicants Gyrus ACMI, Inc. d/b/a Olympus Surgical Technologies America and inventors KONOSTRUM, Gregory S., CHENG, Ming J., and GOLDBERG, Daniel R. The application is classified under IPC A61B 1/00, A61B 1/015, and A61B 1/12, covering diagnostic and surgical instruments. The patent is validated in 31 designated contracting and extension states across Europe.

A-PATH: Adapting Domestic Abuse Support for Women Aged 60-74 (ISRCTN16469112)

University College London is conducting a randomised controlled feasibility study (A-PATH) to adapt an existing domestic abuse support intervention (PATH - Psychological Advocacy Towards Healing) for women aged 60-74 in England and Wales. The trial, registered ISRCTN16469112, is funded by the National Institute for Health and Care Research and approved by the London Stanmore Research Ethics Committee (ref: 26/PR/0105) on 12 March 2026. Recruitment is ongoing with a target sample size of 131 participants across both rural and urban sites, with study completion expected 31 March 2029.

Phase 2b IBS-C Microbiome Therapeutic Trial, UK/US

EnteroBiotix Limited has registered ISRCTN15681288, a Phase 2b randomised, double-blind, placebo-controlled multicentre trial evaluating EBX-102-02, a full-spectrum oral microbiome therapeutic, in approximately 300 adults with moderate to severe IBS with constipation (IBS-C). Participants will be randomised 1:1:1 to EBX-102-02, EBX-102-02 SD, or placebo, with primary efficacy measured by IBS-SSS at 14 weeks. The study has UK ethics approval (ref: 25/LO/0468, approved 16/03/2026) and is expected to run from May 2026 through April 2027 across UK and US sites.

iMAPS Trial: Machine Perfusion Strategies for DCD Liver Transplantation

ISRCTN15444108 (iMAPS) is a Phase II, three-arm, randomized clinical trial sponsored by King's College London and King's College Hospital NHS Foundation Trust, funded by the Medical Research Council (grant MR/X019470/1), investigating three preservation strategies for donation after circulatory death (DCD) human livers: static cold storage (SCS), normothermic regional perfusion (NRP), and hypothermic oxygenated perfusion (HOPE). The trial plans to enroll 36 DCD livers (n=12 per arm) with all livers undergoing subsequent normothermic machine perfusion confirmation before transplantation. Ethics approval was granted 10/11/2023 by the West Midlands – South Birmingham Research Ethics Committee (ref: 23/WM/0226). The study is currently recruiting and runs from March 2025 to December 2026, with the primary objective of determining the effect of different preservation strategies on mitochondrial damage following reperfusion.

End of Life Care Study, Devon Cornwall Somerset, Recruiting

A new clinical trial examining end-of-life care in rural and coastal communities across Devon, Cornwall, and Somerset has been registered and is actively recruiting. The study, sponsored by the University of Plymouth and funded by the National Institute for Health and Care Research (NIHR), began recruiting on 20 February 2026 and is expected to run until January 2028. The target sample size is 320 participants, including patients in the last 12 months of life, family members, and health and social care professionals. The research will employ interviews, surveys, case studies, and workshops to understand current care provision and identify improvement opportunities.

Virtual Reality Café for Young People with Eating Disorders

University of Bristol has registered a feasibility study (ISRCTN37191564) on the ISRCTN clinical trials registry, evaluating a newly developed virtual reality (VR) café intervention for young people aged 14-25 with eating disorders in two NHS trusts. The trial, approved by West of Scotland REC 5 on 27 January 2026 (ref: 25/WS/0200), will recruit participants who will attend up to six 1-hour VR sessions combined with their usual eating disorder treatment, running from June 2026 to October 2027. The study is funded by the National Institute for Health and Care Research (NIHR) and aims to assess recruitment, retention, and acceptability of the VR intervention in NHS settings.

SURVIVE-MI: Sudden Cardiac Death Risk Study, University of Leicester, UK

The SURVIVE-MI clinical trial (ISRCTN17193826) has been registered by the University of Leicester to investigate sudden cardiac death risk in post-myocardial infarction patients. The prospective cohort study will use the non-invasive LifeMap computer test to measure cardiac electrical stability alongside autonomic and mental health assessments. The study runs from April 2026 to September 2029, with ethics approval granted on 03/02/2026 by London South East REC (ref: 26/LO/0063), and is funded by The Kusuma Trust.

Reusable vs Disposable Surgical Drapes NHS Trial

The DRAGON trial (ISRCTN13801317) is a cluster-randomised controlled trial comparing reusable versus disposable surgical drapes and gowns across 32 NHS hospitals in the UK. Funded by the National Institute for Health and Care Research (NIHR) and sponsored by the University of Birmingham, the trial runs from April 2025 to May 2027 and aims to determine whether reusable drapes are as effective as disposables in preventing surgical site infections while reducing environmental impact and costs. The primary outcome is Days Alive and At Home at 30 days (DAH30).

NVG-222 Bispecific T-Cell Engager Phase I/IIa Trial for Solid Tumours, United Kingdom

Cancer Research UK and NovalGen Ltd have registered a Phase I/IIa clinical trial (ISRCTN13633989) for NVG-222, a bispecific T-cell engager targeting ROR1 on cancer cells and CD3 on T cells, in patients with advanced solid tumours. The trial will conduct dose escalation (Phase I) followed by dose expansion (Phase IIa), with participants receiving intravenous infusions once every two weeks starting at 6μg. Ethics approval was granted on 19 January 2026 by the London - Chelsea Research Ethics Committee. The study runs from January 2027 to January 2032, with participants monitored for up to 100 days after their last NVG-222 administration.

MANIFEST Study: Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity

The MANIFEST study (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity) is an observational research study registered as ISRCTN90482257, aiming to recruit approximately 3,000 cancer patients across the United Kingdom to understand why some patients respond well to immunotherapy while others develop treatment-related side effects. The study will collect blood, tumour tissue, stool, and urine samples alongside clinical information from participants receiving standard immunotherapy treatment, with samples analysed for biological and genetic characteristics. The trial is coordinated by The Christie NHS Foundation Trust and funded by the Medical Research Council and the Office for Life Sciences, with recruitment expected to begin in 2026.

Steps Programme Gender-Based Violence Prevention UK Schools ISRCTN94229099

A cluster randomised controlled trial evaluating the Steps programme, a school-based gender-based violence prevention intervention for boys in Years 7-9 (aged 11-14) across Greater Manchester schools. The trial runs from May 2026 to February 2029, comparing boys who receive the six-session Steps programme with a control group continuing normal lessons. The Youth Endowment Fund is both sponsor and funder, with the independent evaluation conducted by Cordis Bright. Ethics approval was granted on 20 March 2026 by the University of Portsmouth Research Ethics Committee.

Effects of Pre-Dive Exercise on Decompression Bubbles

This ANZCTR registration record documents a randomized controlled cross-over trial (ACTRN12626000511336) investigating how pre-dive exercise affects decompression-related venous gas emboli in 40 certified scuba divers. Participants will complete five identical hyperbaric chamber dives to 40 metres depth, with three dives serving as controls and two dives preceded by moderate treadmill or cycling exercise, while researchers monitor microparticle levels, cortisol, C-reactive protein, and sex hormones. The trial received ethics approval and was prospectively registered on 24 April 2026, with all dives conducted at the Slark Hyperbaric Medicine Unit at North Shore Hospital in New Zealand.

SOUND-BITES Hearing Health Checks for MoW Clients, NSW

Macquarie University has registered a clinical trial (ACTRN12626000512325) to assess the acceptability and feasibility of embedding home hearing health checks in NSW Meals on Wheels clients, targeting 600 clients aged 50 years or older. The intervention uses Arclight otoscopic devices and Sound Scouts iPad applications administered by Master of Clinical Audiology students and MoW volunteers. Ethics approval was granted by the Macquarie University Human Research Ethics Committee on 2 April 2026, with recruitment anticipated to begin 4 May 2026 and conclude 12 October 2026. Funding is provided by Macquarie University, Cochlear, and the NSW Smart Sensing Network.

PREDICT-DL: Deep Learning Paediatric ED Admission Prediction Study, Western Australia, Target 35000

The ANZCTR has registered ACTRN12626000513314 for PREDICT-DL, a prospective proof-of-concept study evaluating a continuously deployed machine learning forecasting system that generates hourly ED-cohort-level admission and length-of-stay predictions at a Western Australian paediatric hospital. The study will use an ensemble model (XGboost, multilayer perceptron, TabNET) trained on five years of retrospective data, followed by six months of live prospective validation. Ethics approval was granted by the Child and Adolescent Health Service Human Research Ethics Committee on 10 March 2026, with anticipated first participant enrolment on 1 June 2026 and a target sample size of 35,000 presentations.

Check-BackV2 Rural Chronic Disease Intervention, 208 Participants

ANZCTR has registered a new interventional trial evaluating the Check-BackV2 patient communication resource in rural chronic disease settings. The randomized controlled trial will enroll 208 participants living with chronic conditions including arthritis, asthma, cancer, cardiovascular disease, COPD, diabetes, chronic kidney disease, back pain, and osteoporosis. Participants in the intervention group will receive a 6-page pamphlet, wallet card, and postcard with reminders plus two SMS prompts, alongside access to a co-designed website, while the control group receives usual care. The trial's primary outcome is patient activation, measured at baseline and 12 weeks post-health appointment, with secondary outcomes including feeling understood by clinicians, health system navigation, medication adherence, and hospital/ED presentations.

Dropless Cataract Surgery RCT: Subconjunctival Triamcinolone Injection vs Topical Steroid Drops

A prospective randomized non-inferiority clinical trial has been registered with the Australian New Zealand Clinical Trials Registry (ACTRN12626000516381p) comparing a single intraoperative subconjunctival triamcinolone acetonide 5 mg injection (intervention) against a four-week regimen of Prednefrin Forte topical steroid eye drops (comparator) in patients undergoing phacoemulsification cataract surgery. The primary outcome is change in central macular thickness from baseline measured at 3 weeks and 8 weeks post-intervention. Ethics application status is submitted but not yet approved as of the registration date of 24 April 2026. The study is conducted by Bayside Health within Melbourne and is registered prospectively.

Novel Indirect Bonding Technique for Clear Aligner Attachments: Split-Mouth Randomized Controlled Trial Registration

ANZCTR registered clinical trial ACTRN12626000515392 comparing a novel indirect bonding technique against conventional direct bonding for clear aligner attachment placement in orthodontic patients with malocclusion. The split-mouth randomized controlled trial enrolled 21 participants in Shaanxi Province, China, with first enrolment on 5 February 2026 and last enrolment on 12 March 2026. The experimental intervention uses digitally planned attachment positions from intraoral scans and 3D-printed transfer trays, while the primary outcome measures three-dimensional placement accuracy.

POLB 001 Phase I/II Trial Prevents CRS in Myeloma Patients Taking Teclistamab

ISRCTN50499387 registers a non-randomised, single-arm, open-label Phase I/II clinical trial (TOPICAL) evaluating POLB 001, an oral small molecule inhibitor, for the prevention of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma receiving the bispecific T-cell engager antibody teclistamab. Approximately 30 evaluable patients will be enrolled across 6 UK hospitals, taking POLB 001 for 14 days beginning immediately before their first teclistamab dose, then continuing teclistamab for 2 cycles (8 weeks) on-trial before transitioning to NHS-supplied teclistamab. The study is prospectively registered and was submitted for ethics approval on 09/01/2026 (ref: 26/WM/0017); recruitment opens March 2026 and the study is expected to run through June 2027. The primary objectives are safety and early efficacy of POLB 001; secondary objectives include assessment of CRS incidence and severity, teclistamab response, and pharmacokinetics of POLB 001.

Respiratory-Swallow Training in Head and Neck Cancer

The University of Liverpool is sponsoring a clinical trial testing simplified respiratory-swallow training for patients with swallowing difficulties following head and neck cancer treatment. The trial, funded by the National Institute for Health and Care Research (NIHR), will recruit participants who have completed cancer treatment at least three months ago and are able to drink fluids. Participants will receive £20 and travel expenses for every appointment attended. The trial aims to develop an accessible training programme that can be delivered by speech and language therapists in NHS clinics or at home.

MANIFEST Study: Multiomic Analysis of Immunotherapy Response and Toxicity in UK Cancer Patients

The MANIFEST study (ISRCTN90482257) is an observational cancer immunotherapy research trial registered with the Health Research Authority and coordinated by The Christie NHS Foundation Trust. The study aims to recruit approximately 3,000 patients across UK hospitals to collect biological samples (blood, tumour tissue, stool, urine) and clinical data from cancer patients receiving immunotherapy treatment. Researchers will analyse these samples to identify patterns that may explain why some patients respond well to immunotherapy while others develop treatment-related side effects. The study is funded by the Medical Research Council and the Office for Life Sciences, with Professor Samra Turajlić serving as Chief Investigator.

NVG-222 Phase I/IIa Cancer Drug Trial for Solid Tumours

Cancer Research UK is sponsoring a Phase I/IIa open-label dose escalation and expansion trial of NVG-222, a bispecific ROR1-directed CD3 T-cell engager, in participants with advanced solid tumours. The trial received ethics approval from the London - Chelsea Research Ethics Committee on 19 January 2026 (ref: 25/LO/0829) and is prospectively registered. Recruitment is scheduled to begin in January 2027 with an estimated completion date of January 2032. The trial is funded jointly by Cancer Research UK and NovalGen Ltd.

JNJ-79635322 vs Teclistamab Phase 3 Multiple Myeloma Trial

Janssen-Cilag International NV has registered a Phase 3 randomized trial (Trilogy-4, ISRCTN80147609) comparing its investigational drug JNJ-79635322 against the approved BCMAxCD3 bispecific antibody teclistamab in patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy. The trial is currently recruiting and is designed as an open-label, parallel-assignment study with an active comparator. Participants will be randomized to receive either JNJ-79635322 or teclistamab as subcutaneous injections, with safety monitoring including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome assessments. The study runs from March 2026 through approximately June 2027.

TROPICCANA Study: HPV Blood Test for Cervical Cancer Treatment Monitoring, Recruiting

The TROPICCANA observational cohort study is recruiting adults over 18 years with locally advanced cervix cancer receiving chemoradiation. The study, run by The Royal Marsden NHS Foundation Trust, evaluates HPV-detect (a circulating HPV DNA test using ddPCR) as a predictor of residual disease following primary chemoradiotherapy. Participants will donate one blood sample before treatment and up to eight blood samples during treatment and follow-up, with disease status collected for up to 3 years. The study runs from January 2026 to July 2030 and is funded by the Lady Garden Foundation and CRUK RM/ICR RadNet Centre.

PRIMED Study: Cluster Randomized Trial in Nigeria and Kenya to Reduce Cancer Diagnostic Delays

The PRIMED (PRImary care Management to Enhance early cancer Diagnosis) study is a cluster randomized controlled trial registered with ISRCTN (ISRCTN58974446) evaluating a multicomponent intervention to reduce delays in cancer diagnosis in Nigeria and Kenya. The trial will run from April 2026 to April 2028, randomly assigning 225 clusters (75 per arm: intervention, crossover, or control) across three sites to test provider education, clinic strengthening, and patient navigation support. Primary outcomes include quality of primary care consultations, healthcare provider knowledge, and proportion of patients reaching resolution within four months.